Highlights
- 1
- 2Expert review of anti-infective therapy · 2022
- 3Expert review of molecular diagnostics · 2022
Publications
114 publications
Funding
6 grants
Active
3 grants- MPIOT2HL156812-01RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)National Heart, Lung, and Blood Institute · 2022–2026 · via Duke University· 4 renewals
- MPIUM1AI104681-09Dalbavancin as an Option for Treatment of S. aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients with Complicated S. aureus BacteremiaNational Institute of Allergy and Infectious Diseases · 2020–2026 · via Duke University
- Co-IAAMC 228122-01Tele-ACES (Appropriate Care and Escalation Strategies): A Simulation-Based Curriculum and Assessment to Teach Patient Safety in TelemedicineAssociation of American Medical Colleges · 2023–2026
Completed grants (3)
- KP75N91020F00039/ 18X107CF6International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) 018 STRIVE Platform TrialNational Institute of Allergy and Infectious Diseases · 2022–2025 · via Institute for Clinical Research
- Sub-PIU24TR001608-07S1ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed MedicationsNational Center for Advancing Translational Sciences · 2021–2025 · via Duke University
- Sub-PIHHSO100201400002IRandomized Blinded Controlled Trial of the Safety and Efficacy of Multiple Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTIV-1)Biomedical Advanced Research and Development Authority · 2020–2024 · via Duke University
Clinical research
8 studies
Completed & closed trials (8)
- PINCT05605093Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease InhibitorPHASE3 · University of Minnesota · IRB STUDY CLOSURE (as of 2026)COVID-19
- PINCT05822583Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy TrialPHASE4 · University of Minnesota · IRB STUDY CLOSURE (as of 2025)COVID-19
- PINCT06181669Pneumonia Direct PilotDuke University · IRB STUDY CLOSURE (as of 2025)Pneumonia, Bacterial; Ventilator Associated Pneumonia
- PINCT05595369RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)PHASE2 · Duke University · IRB STUDY CLOSURE (as of 2025)Long COVID; Long Covid19
- PINCT04775953Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus BacteremiaPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)Staphylococcal Bacteraemia
- PINCT04885530ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed MedicationsPHASE3 · Duke University · IRB STUDY CLOSURE (as of 2024)Covid19
- PINCT04505774A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19PHASE4 · University of Pittsburgh · IRB STUDY CLOSURE (as of 2024)Covid19
- PINCT04593940Randomized Master Protocol for Immune Modulators for Treating COVID-19PHASE3 · National Center for Complementary and Integrative Health/NIH/DHHS · IRB STUDY CLOSURE (as of 2022)Covid19
External relationships
Other
Davis Polk & Wardwell LLP